Limits...
Extramural extension as indicator for postoperative adjuvant chemotherapy in Stage IIA (pT3N0) colon cancer.

Akagi Y, Shirouzu K, Kinugasa T - J Surg Oncol (2013)

Bottom Line: The optimal prognostic cut-off point of the DEE for oncologic outcomes was statistically determined.The pT3b was the most powerful independent risk factor for postoperative recurrence (P = 0.0324, HR: 3.04, 95% CI: 1.098-8.408), and was significantly correlated with distant metastasis (P = 0.0161 HR: 5.19, 95% CI: 1.765-15.239).Postoperative adjuvant CMT may be indicated for patients with pT3b.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan.

Show MeSH

Related in: MedlinePlus

Recurrence-free survival. The recurrence-free 5-year-survival rate was 81.5% in patients with pT3b, and 95.4% in patients with pT3a. Significant difference was noted between the groups (P = 0.0003, HR: 4.71, 95% CI: 1.875–11.849). pT3a, distance of extramural extension ≤5 mm; pT3b, distance of extramural extension >5 mm.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4217392&req=5

fig03: Recurrence-free survival. The recurrence-free 5-year-survival rate was 81.5% in patients with pT3b, and 95.4% in patients with pT3a. Significant difference was noted between the groups (P = 0.0003, HR: 4.71, 95% CI: 1.875–11.849). pT3a, distance of extramural extension ≤5 mm; pT3b, distance of extramural extension >5 mm.

Mentions: As shown in Figure 3, the recurrence-free 5-year-survival rate was significantly lower in patients with pT3b than in patients with pT3a (81.5% vs. 95.4%, P = 0.0003, HR: 4.71, 95% CI: 1.875–11.849). In addition, the cancer-specific 5-year-survival rate in patients with pT3b was significantly lower than that in patients with pT3a (85.9% vs. 97.4%, P = 0.0007, HR: 5.84, 95% CI: 1.831–18.632) as shown in Figure 4.


Extramural extension as indicator for postoperative adjuvant chemotherapy in Stage IIA (pT3N0) colon cancer.

Akagi Y, Shirouzu K, Kinugasa T - J Surg Oncol (2013)

Recurrence-free survival. The recurrence-free 5-year-survival rate was 81.5% in patients with pT3b, and 95.4% in patients with pT3a. Significant difference was noted between the groups (P = 0.0003, HR: 4.71, 95% CI: 1.875–11.849). pT3a, distance of extramural extension ≤5 mm; pT3b, distance of extramural extension >5 mm.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4217392&req=5

fig03: Recurrence-free survival. The recurrence-free 5-year-survival rate was 81.5% in patients with pT3b, and 95.4% in patients with pT3a. Significant difference was noted between the groups (P = 0.0003, HR: 4.71, 95% CI: 1.875–11.849). pT3a, distance of extramural extension ≤5 mm; pT3b, distance of extramural extension >5 mm.
Mentions: As shown in Figure 3, the recurrence-free 5-year-survival rate was significantly lower in patients with pT3b than in patients with pT3a (81.5% vs. 95.4%, P = 0.0003, HR: 4.71, 95% CI: 1.875–11.849). In addition, the cancer-specific 5-year-survival rate in patients with pT3b was significantly lower than that in patients with pT3a (85.9% vs. 97.4%, P = 0.0007, HR: 5.84, 95% CI: 1.831–18.632) as shown in Figure 4.

Bottom Line: The optimal prognostic cut-off point of the DEE for oncologic outcomes was statistically determined.The pT3b was the most powerful independent risk factor for postoperative recurrence (P = 0.0324, HR: 3.04, 95% CI: 1.098-8.408), and was significantly correlated with distant metastasis (P = 0.0161 HR: 5.19, 95% CI: 1.765-15.239).Postoperative adjuvant CMT may be indicated for patients with pT3b.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan.

Show MeSH
Related in: MedlinePlus